Theriva Biologics, Inc. Preferred Stock Dividends, Income Statement Impact
Theriva Biologics, Inc. (TOVX) reported Preferred Stock Dividends, Income Statement Impact of $254.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2021-03-04
- Theriva Biologics, Inc. preferred stock dividends, income statement impact for the quarter ending 2019-12-31 was $63.00K, a 1.61% increase year-over-year.
- Theriva Biologics, Inc. preferred stock dividends, income statement impact for the quarter ending 2018-12-31 was $62.00K.
- Theriva Biologics, Inc. preferred stock dividends, income statement impact for the quarter ending 2018-09-30 was $61.00K, a 99.12% decline year-over-year.
- Theriva Biologics, Inc. preferred stock dividends, income statement impact for the quarter ending 2018-06-30 was $61.00K.
- Theriva Biologics, Inc. preferred stock dividends, income statement impact for fiscal 2020 was $254.00K, a 2.42% increase from fiscal 2019.
- Theriva Biologics, Inc. preferred stock dividends, income statement impact for fiscal 2019 was $248.00K, a 2.06% increase from fiscal 2018.
- Theriva Biologics, Inc. preferred stock dividends, income statement impact for fiscal 2018 was $243.00K.
- Theriva Biologics, Inc. preferred stock dividends, income statement impact for fiscal 2016 was $0.00.
| Period end | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 6 month | Preferred Stock Dividends, Income Statement Impact 9 month | Preferred Stock Dividends, Income Statement Impact 12 month | Preferred Stock Dividends, Income Statement Impact 12 month as first filed |
|---|---|---|---|---|---|
| 2020-12-31 | $254.00K 10-K · filed 2021-03-04 | ||||
| 2019-12-31 | $63.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $248.00K 10-K · filed 2021-03-04 | |||
| 2019-09-30 | $185.00K 10-Q · filed 2020-11-10 | ||||
| 2018-12-31 | $62.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-20 | $123.00K derived: sum of 2 quarters · filed 2020-02-20 | $184.00K derived: sum of 3 quarters · filed 2020-02-20 | $243.00K 10-K · filed 2020-02-20 | |
| 2018-09-30 | $61.00K 10-Q · filed 2018-11-08 | $122.00K derived: sum of 2 quarters · filed 2018-11-08 | $181.00K 10-Q · filed 2018-11-08 | $180.00K derived: sum of 4 quarters · filed 2019-05-08 | |
| 2018-06-30 | $61.00K 10-Q · filed 2018-08-08 | $120.00K 10-Q · filed 2018-08-08 | $119.00K derived: sum of 3 quarters · filed 2019-05-08 | $7.02M derived: sum of 4 quarters · filed 2019-05-08 | |
| 2018-03-31 | $59.00K 10-Q · filed 2018-05-08 | $58.00K derived: sum of 2 quarters · filed 2019-05-08 | $6.96M derived: sum of 3 quarters · filed 2019-05-08 | $6.96M derived: sum of 4 quarters · filed 2019-05-08 | |
| 2017-12-31 | -$1.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2019-05-08 | $6.90M derived: sum of 2 quarters · filed 2019-05-08 | $6.90M derived: sum of 3 quarters · filed 2019-05-08 | $6.90M 10-Q · filed 2019-05-08 | $6.96M 10-K · filed 2018-02-22 |
| 2017-09-30 | $6.90M 10-Q · filed 2018-11-08 | $6.90M derived: sum of 2 quarters · filed 2018-11-08 | $6.90M 10-Q · filed 2018-11-08 | $6.90M derived: sum of 4 quarters · filed 2018-11-08 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $0.00 10-Q · filed 2018-08-08 | $0.00 derived: sum of 3 quarters · filed 2018-08-08 | $0.00 derived: sum of 4 quarters · filed 2018-08-08 | |
| 2017-03-31 | $0.00 10-Q · filed 2018-05-08 | $0.00 derived: sum of 2 quarters · filed 2018-05-08 | $0.00 derived: sum of 3 quarters · filed 2018-05-08 | ||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $0.00 derived: sum of 2 quarters · filed 2018-02-22 | $0.00 10-K · filed 2018-02-22 | ||
| 2016-09-30 | $0.00 10-Q · filed 2017-11-01 | $0.00 10-Q · filed 2017-11-01 | |||
| 2015-12-31 | $0.00 10-K · filed 2018-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |